LearnGlossaryMarketStocksSuperinvestorsSign in

PRTA

Prothena Corporation plc

Healthcare · $457M market cap

Verdict

We can't put a fair value on PRTA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-2.5% a year✗
Sales growth21.7% a year✓
Free cash flow growth—?
Return on invested capital-40.2%✗

Follow PRTA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 2, 2026: 1 open-market purchase worth $256K. Why purchases matter

Purchases

SCULLY WILLIAM P

Owns 10%+ · 2026-09-02

Bought

$256K

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works